Familial Cancer 2025
Top Research Directions
The 2 research directions with Familial Cancer 2025 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.
| # | Direction | Papers | Share |
|---|---|---|---|
| 1 | Cross-Sectional Surveys for Point-in-Time Population Insights | 1 | 100.0% |
| 2 | Interpersonal Interaction as a Proxy for Technical Quality | 1 | 100.0% |
Download all directions as CSV
Institutions
Institutions credited by Familial Cancer 2025 papers: a paper credits every institution named in its affiliations, once. 4 institutions share 1 credited papers.
| # | Institution | Papers | Share |
|---|---|---|---|
| 1 | Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences | 1 | 100.0% |
| 2 | Oslo University Hospital | 1 | 100.0% |
| 3 | OsloMet – Oslo Metropolitan University | 1 | 100.0% |
| 4 | University of Oslo | 1 | 100.0% |
Download all institutions as CSV
About this data
Papers. Familial Cancer 2025 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.
Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.
Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.
Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Familial Cancer 2025”, https://lacuna.tiptreesystems.com/venue/familial-cancer/2025.
Top Authors
| Author | Papers |
|---|---|
| Amy Østertun Geirdal | 1 |
| Astrid Stormorken | 1 |
| Hanne Kjensli Hyldebrandt | 1 |
Papers
| Title |
|---|
| Experiences with risk-reducing mastectomy in Norwegian BRCA1/2 carriers without prior breast cancer |